エピジェネティック医薬品・診断技術の世界市場

エピジェネティック医薬品・診断技術の世界市場は2030年までに261億米ドルに到達

2024年に94億米ドルと推定されるエピジェネティック医薬品・診断技術の世界市場は、2024年から2030年にかけてCAGR 18.6%で成長し、2030年には261億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるDNAメチル化は、CAGR 16.8%を記録し、分析期間終了までに58億米ドルに達すると予測されます。ヒストンメチル化セグメントの成長率は、分析期間中CAGR 20.9%と推定されます。

米国市場は26億米ドルと推定される一方、中国はCAGR 24.1％で成長すると予測される

米国のエピジェネティック医薬品・診断技術市場は、2024年には26億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに58億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは24.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ14.1%と16.6%と予測されています。欧州では、ドイツがCAGR約14.8%で成長すると予測されています。

世界のエピジェネティック医薬品・診断技術市場- 主要動向と促進要因のまとめ

なぜエピジェネティック医薬品・診断技術が精密医療の未来を変えるのか？

エピジェネティック医薬品・診断技術は、基礎となるDNA配列を変えることなく遺伝子発現を可逆的に変化させることをターゲットとすることで、プレシジョン・メディシンの展望を再定義しています。永続的な従来の遺伝子変異とは異なり、エピジェネティックな変化（DNAメチル化、ヒストン修飾、クロマチンリモデリングなど）は、環境要因、ライフスタイル、疾患の進行によって影響を受ける可能性があります。これらの変化は、がん、神経疾患、自己免疫疾患、代謝症候群などの複雑な疾患の開発において重要な役割を果たしています。その結果、エピジェネティック技術は、従来の薬剤では治療が困難であった疾患に対して、新たな治療手段を提供することになります。DNAメチルトランスフェラーゼ阻害剤やヒストン脱アセチル化酵素阻害剤などのエピジェネティック医薬品は、がん細胞を再プログラムし、がん抑制遺伝子の発現を回復させ、免疫療法に対して腫瘍を感作するために、すでに腫瘍学で使用されています。エピジェネティック・バイオマーカーを活用した診断ツールも同様に変革的であり、リキッドバイオプシーのような非侵襲的検査を通じて、疾患の早期発見、患者の層別化、治療モニタリングを可能にしています。これらの診断プラットフォームは、特定の疾患に関連するメチル化パターンやクロマチン状態を検出することができ、真に個別化された治療への道を開きます。治療パラダイムを対症療法から根本治療へとシフトさせるこの分野の可能性により、エピジェネティック医薬品・診断技術は次世代医療の礎石となり、分子生物学と臨床イノベーションを融合させ、インパクトのあるヘルスケアソリューションを提供しています。

科学の進歩はエピジェネティック治療薬とバイオマーカーの進化をどのように促しているのか？

分子生物学、バイオインフォマティクス、ゲノム技術における急速な科学的進歩は、エピジェネティック治療薬や診断薬の開発を加速し、より高い特異性、有効性、拡張性をもたらしています。次世代シークエンシング（NGS）、シングルセル解析、CRISPRベースのエピジェネティック編集の進歩により、研究者はこれまでにない解像度でヒトエピゲノムをマッピングし、新規の創薬ターゲットやバイオマーカーシグネチャーを発見できるようになっています。ハイスループットスクリーニングツールは、現在、薬剤候補に反応するエピジェネティック修飾のリアルタイム評価を可能にし、リードの最適化と前臨床検証を向上させています。治療領域では、研究者は、第一世代の薬剤の初期の限界を克服し、選択性の向上と標的外作用の低減を示す第二世代のエピジェネティック・モジュレーターを開発しています。ブロモドメイン阻害剤、ヒストン・メチルトランスフェラーゼ阻害剤、エピジェネティック免疫モジュレーターなどの新しいアプローチは、治療のレパートリーを血液がんだけでなく、固形がん、神経変性疾患、炎症性疾患にも広げています。診断面では、複雑なエピジェネティックデータの解釈に機械学習アルゴリズムが採用され、予測力と臨床的意思決定が強化されつつあります。DNAメチル化アレイやクロマチンアクセシビリティアッセイのようなプラットフォームは現在、疾患の早期発見と進行のモニタリングを促進するために臨床ワークフローに組み込まれています。エピジェネティック医薬品とともに共同開発されたコンパニオン診断薬は、最も反応性の高い患者のみが標的治療を受けられるようにし、転帰を最大化し、不必要な被曝を減らしています。このような科学的イノベーションにより、エピジェネティックツールはより正確で実用的、かつインパクトのあるものとなり、バイオマーカーに導かれた治療・診断の新時代が育まれつつあります。

エピジェネティック・ソリューションに対する需要が疾患領域や世界市場全体で高まっているのはなぜですか？

エピジェネティック医薬品・診断技術に対する需要は、慢性疾患や複雑な疾患の有病率の増加、満たされていない臨床ニーズ、個別化医療への世界のシフトを背景に、複数の治療領域や世界ヘルスケア市場において急速に拡大しています。早期発見と個別化治療が重要な腫瘍学では、エピジェネティック検査が腫瘍のサブタイプ分類、治療反応の予測、低侵襲的な方法による再発の追跡に広く採用されています。がん以外にも、エピジェネティックな解決策は、アルツハイマー病やパーキンソン病など、遺伝子発現パターンの異常が病態の一因となる疾患に対する神経学で研究されています。自己免疫疾患や炎症性疾患では、エピジェネティックな調節が、広範な免疫抑制なしに免疫応答を再調整する有望な戦略として浮上しています。遺伝子変異だけでは発症を説明できない小児疾患や希少疾患も、エピジェネティックな知見から恩恵を受けています。世界規模では、新興経済諸国がエピジェネティック診断法を採用し始めています。これは、費用対効果の高い早期疾患発見の可能性があるためであり、特に従来のヘルスケアへのアクセスが制限されている地域において顕著です。さらに、糖尿病や肥満などの生活習慣病が増加していることから、食事やストレス、環境が疾患に分子レベルでどのように影響するかを理解するためのエピジェネティック研究への関心が高まっています。北米、欧州、アジア太平洋の製薬会社、診断薬会社、研究機関は、多様な集団に価値の高い低毒性ソリューションを提供できる可能性を認識し、エピジェネティクスに多額の投資を行っています。認知度とアクセスが高まるにつれて、エピジェネティック・ソリューションの需要は大幅に拡大し、世界中のヘルスケア提供と疾病管理を再構築すると予想されます。

エピジェネティック医薬品・診断技術市場の成長を促進する主な要因は何ですか？

エピジェネティック医薬品・診断技術市場の成長は、科学的発見、市場の準備、精密医療と早期介入を支持するヘルスケア政策のシフトの組み合わせによって促進されます。主な促進要因のひとつは、がんや複雑な慢性疾患の罹患率の増加であり、これらの疾患は、標的を絞った個別化治療戦略を必要とします。特にFDAやEMAのような機関によるエピジェネティック医薬品やコンパニオン診断薬に対する規制上の支援と促進された経路は、より迅速な市場参入とイノベーションの採用を促進しています。投資動向もこの分野の勢いを反映しており、ベンチャーキャピタルからの多額の資金調達、政府研究助成金、バイオテクノロジー企業と製薬企業の戦略的提携が研究開発パイプラインを後押ししています。ビッグデータ解析、AI、クラウドベースのバイオインフォマティクス・プラットフォームの融合は、エピジェネティック・ソリューションの拡張性と臨床的有用性を高め、プロバイダーや支払者にとってより魅力的なものとなっています。エピジェネティック検査の臨床試験への統合が、特にがん領域で増加しており、バイオマーカーの検証や薬剤の適応拡大に役立っています。個別化され、侵襲性の低い診断やより効果的な治療を求める患者の需要も、市場の加速に重要な役割を果たしています。さらに、進行中のヘルスケアシステムのデジタル化は、エピジェネティック診断の普及に不可欠な、より広範なデータ共有と相互運用性を可能にしています。これらの促進要因が、予防医療、疾病の阻止、患者中心の転帰をより重視することと整合するにつれ、エピジェネティック技術市場は、臨床、商業、地理的フロンティアにわたって、堅調かつ持続的な成長を遂げる態勢が整ってきています。

セグメント

技術（DNAメチル化、ヒストンメチル化、ヒストンアセチル化、Large Noncoding RNA、MicroRNA修飾、クロマチン構造）、治療（HDAC治療、DNMT治療）、用途（腫瘍学、非腫瘍学）

調査対象企業の例（注目の41社）

• Abcam PLC
• Active Motif, Inc.
• Bio-Rad Laboratories, Inc.
• Cantata Bio
• CellCentric Ltd.
• Chroma Medicine
• Constellation Pharmaceuticals, Inc.
• Diagenode s.a.
• Domainex Ltd.
• Dovetail Genomics LLC
• Element Biosciences, Inc.
• Eisai Co., Ltd.
• Epigenomics AG
• Epizyme, Inc.
• Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Merck KGaA
• Novartis AG
• Qiagen N.V.
• Thermo Fisher Scientific Inc.

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Epigenetic Drug and Diagnostic Technology Market to Reach US$26.1 Billion by 2030

The global market for Epigenetic Drug and Diagnostic Technology estimated at US$9.4 Billion in the year 2024, is expected to reach US$26.1 Billion by 2030, growing at a CAGR of 18.6% over the analysis period 2024-2030. DNA Methylation, one of the segments analyzed in the report, is expected to record a 16.8% CAGR and reach US$5.8 Billion by the end of the analysis period. Growth in the Histone Methylation segment is estimated at 20.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 24.1% CAGR

The Epigenetic Drug and Diagnostic Technology market in the U.S. is estimated at US$2.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.8 Billion by the year 2030 trailing a CAGR of 24.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.1% and 16.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.8% CAGR.

Global Epigenetic Drug and Diagnostic Technology Market - Key Trends & Drivers Summarized

Why Is Epigenetic Drug and Diagnostic Technology Transforming the Future of Precision Medicine?

Epigenetic drug and diagnostic technology is redefining the landscape of precision medicine by targeting reversible modifications to gene expression without altering the underlying DNA sequence. Unlike traditional genetic mutations that are permanent, epigenetic changes-such as DNA methylation, histone modification, and chromatin remodeling-can be influenced by environmental factors, lifestyle, and disease progression. These changes play a crucial role in the development of complex diseases, including cancer, neurological disorders, autoimmune conditions, and metabolic syndromes. As a result, epigenetic technologies offer a novel therapeutic window for diseases that were previously difficult to treat with conventional drugs. Epigenetic drugs, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, are already being used in oncology to reprogram cancer cells, restore tumor suppressor gene expression, and sensitize tumors to immunotherapy. Diagnostic tools leveraging epigenetic biomarkers are proving equally transformative, enabling early disease detection, patient stratification, and treatment monitoring through non-invasive tests like liquid biopsies. These diagnostic platforms can detect methylation patterns or chromatin states associated with specific diseases, paving the way for truly personalized care. The field’s potential to shift treatment paradigms from symptom management to root-cause targeting has made epigenetic drug and diagnostic technology a cornerstone of next-generation medicine, blending molecular biology with clinical innovation for impactful healthcare solutions.

How Are Scientific Advancements Driving the Evolution of Epigenetic Therapeutics and Biomarkers?

Rapid scientific progress in molecular biology, bioinformatics, and genomic technologies is accelerating the development of epigenetic drugs and diagnostics, leading to greater specificity, efficacy, and scalability. Advances in next-generation sequencing (NGS), single-cell analysis, and CRISPR-based epigenetic editing are allowing researchers to map the human epigenome with unprecedented resolution, uncovering novel drug targets and biomarker signatures. High-throughput screening tools now enable real-time assessment of epigenetic modifications in response to drug candidates, improving lead optimization and preclinical validation. In the therapeutic domain, researchers are developing second-generation epigenetic modulators that exhibit improved selectivity and reduced off-target effects, overcoming early limitations of first-wave drugs. Novel approaches such as bromodomain inhibitors, histone methyltransferase inhibitors, and epigenetic immune modulators are expanding the therapeutic repertoire beyond hematologic cancers to solid tumors, neurodegenerative diseases, and inflammatory conditions. On the diagnostic side, machine learning algorithms are being employed to interpret complex epigenetic data, enhancing predictive power and clinical decision-making. Platforms like DNA methylation arrays and chromatin accessibility assays are now being integrated into clinical workflows to facilitate early detection and monitoring of disease progression. Companion diagnostics, co-developed alongside epigenetic drugs, are ensuring that only the most responsive patients receive targeted therapies-maximizing outcomes and reducing unnecessary exposure. These scientific innovations are making epigenetic tools more precise, practical, and impactful, fostering a new era of biomarker-guided therapeutics and diagnostics.

Why Is Demand for Epigenetic Solutions Rising Across Disease Areas and Global Markets?

The demand for epigenetic drug and diagnostic technology is growing rapidly across multiple therapeutic areas and global healthcare markets, driven by the increasing prevalence of chronic and complex diseases, unmet clinical needs, and the global shift toward personalized medicine. In oncology, where early detection and individualized treatment are critical, epigenetic tests are being widely adopted to classify tumor subtypes, predict treatment response, and track recurrence through minimally invasive methods. Beyond cancer, epigenetic solutions are being explored in neurology for diseases such as Alzheimer’s and Parkinson’s, where abnormal gene expression patterns contribute to disease pathology. In autoimmune and inflammatory diseases, epigenetic modulation is emerging as a promising strategy to recalibrate immune responses without broad immunosuppression. Pediatric and rare diseases, where genetic mutations alone do not explain disease onset, are also benefiting from epigenetic insights. On a global scale, developing economies are beginning to adopt epigenetic diagnostics due to their potential for cost-effective, early disease detection-especially in regions where traditional healthcare access is limited. Additionally, the rise in lifestyle-related disorders such as diabetes and obesity is driving interest in epigenetic research to understand how diet, stress, and environment influence disease at a molecular level. Pharmaceutical companies, diagnostics firms, and research institutions across North America, Europe, and Asia-Pacific are investing heavily in epigenetics, recognizing its potential to deliver high-value, low-toxicity solutions across diverse populations. As awareness and access grow, demand for epigenetic solutions is expected to expand significantly, reshaping healthcare delivery and disease management worldwide.

What Are the Key Drivers Fueling the Growth of the Epigenetic Drug and Diagnostic Technology Market?

The growth in the epigenetic drug and diagnostic technology market is fueled by a combination of scientific discovery, market readiness, and healthcare policy shifts that favor precision medicine and early intervention. One of the primary drivers is the increasing incidence of cancer and complex chronic diseases that require targeted and individualized treatment strategies-an area where epigenetics provides a unique advantage. Regulatory support and accelerated pathways for epigenetic drugs and companion diagnostics, particularly from agencies like the FDA and EMA, are facilitating faster market entry and innovation adoption. Investment trends also reflect the sector’s momentum, with significant funding from venture capital firms, government research grants, and strategic partnerships between biotech and pharma companies fueling R&D pipelines. The convergence of big data analytics, AI, and cloud-based bioinformatics platforms is enhancing the scalability and clinical utility of epigenetic solutions, making them more attractive to providers and payers. Increasing integration of epigenetic tests into clinical trials, particularly in oncology, is helping validate biomarkers and expand drug indications. Patient demand for personalized, less invasive diagnostics and more effective treatments is also playing a crucial role in market acceleration. Furthermore, the ongoing digitalization of healthcare systems is enabling broader data sharing and interoperability, essential for the widespread adoption of epigenetic diagnostics. As these drivers align with a broader emphasis on preventive care, disease interception, and patient-centered outcomes, the epigenetic technology market is poised for robust and sustained growth across clinical, commercial, and geographic frontiers.

SCOPE OF STUDY:

The report analyzes the Epigenetic Drug and Diagnostic Technology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification, Chromatin Structures); Therapy (HDAC Therapy, DNMT Therapy); Application (Oncology, Non-Oncology)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Abcam PLC
• Active Motif, Inc.
• Bio-Rad Laboratories, Inc.
• Cantata Bio
• CellCentric Ltd.
• Chroma Medicine
• Constellation Pharmaceuticals, Inc.
• Diagenode s.a.
• Domainex Ltd.
• Dovetail Genomics LLC
• Element Biosciences, Inc.
• Eisai Co., Ltd.
• Epigenomics AG
• Epizyme, Inc.
• Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Merck KGaA
• Novartis AG
• Qiagen N.V.
• Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Epigenetic Drug and Diagnostic Technology - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rise in Oncology Incidence Throws the Spotlight on Epigenetic Therapeutics and Biomarkers
  • Unmet Needs in Precision Medicine Propel Growth in Targeted Epigenetic Modulators
  • Expansion of Companion Diagnostics Market Expands Addressable Opportunity for Epigenetic Testing
  • Advances in Next-Generation Sequencing Strengthen the Business Case for Methylation-Based Diagnostics
  • Growing Research on Chromatin Remodeling Accelerates Development of Novel Therapeutic Targets
  • Push for Early Detection in Cancer Care Spurs Demand for Non-Invasive Epigenetic Screening Tools
  • Neurodegenerative Disease Research Generates Interest in Histone Deacetylase Inhibitors and Related Therapies
  • Integration of Multi-Omics Platforms Fuels Innovation in Epigenetic Drug Discovery Pipelines
  • Patient Stratification and Predictive Biomarkers Drive Adoption in Clinical Trial Design
  • Rare Disease Pipeline Expansion Spurs Development of Epigenetic Modulators with Orphan Designation
  • AI-Powered Drug Discovery Platforms Accelerate Screening and Optimization of Epigenetic Compounds
  • Growth of Liquid Biopsy Ecosystem Enhances Delivery of Epigenetic Diagnostic Solutions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Epigenetic Drug and Diagnostic Technology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Epigenetic Drug and Diagnostic Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for DNA Methylation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for DNA Methylation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for DNA Methylation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Histone Methylation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Histone Methylation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Histone Methylation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Histone Acetylation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Histone Acetylation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Histone Acetylation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Large Noncoding RNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Large Noncoding RNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Large Noncoding RNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for MicroRNA Modification by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for MicroRNA Modification by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for MicroRNA Modification by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Chromatin Structures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Chromatin Structures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Chromatin Structures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Non-Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Non-Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Non-Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for HDAC Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for HDAC Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for HDAC Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for DNMT Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for DNMT Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for DNMT Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Epigenetic Drug and Diagnostic Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• JAPAN
  • Epigenetic Drug and Diagnostic Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• CHINA
  • Epigenetic Drug and Diagnostic Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• EUROPE
  • Epigenetic Drug and Diagnostic Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Epigenetic Drug and Diagnostic Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• FRANCE
  • Epigenetic Drug and Diagnostic Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• GERMANY
  • Epigenetic Drug and Diagnostic Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Epigenetic Drug and Diagnostic Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Epigenetic Drug and Diagnostic Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Epigenetic Drug and Diagnostic Technology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Epigenetic Drug and Diagnostic Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• INDIA
  • Epigenetic Drug and Diagnostic Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Epigenetic Drug and Diagnostic Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Epigenetic Drug and Diagnostic Technology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Epigenetic Drug and Diagnostic Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Epigenetic Drug and Diagnostic Technology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030
• AFRICA
  • Epigenetic Drug and Diagnostic Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Epigenetic Drug and Diagnostic Technology by Technology - DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Technology - Percentage Breakdown of Value Sales for DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification and Chromatin Structures for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Epigenetic Drug and Diagnostic Technology by Application - Non-Oncology and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Application - Percentage Breakdown of Value Sales for Non-Oncology and Oncology for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Epigenetic Drug and Diagnostic Technology by Therapy - HDAC Therapy and DNMT Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Epigenetic Drug and Diagnostic Technology by Therapy - Percentage Breakdown of Value Sales for HDAC Therapy and DNMT Therapy for the Years 2015, 2025 & 2030

IV. COMPETITION